APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chagas Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Research

Chagas Disease Treatment Industry Research Report 2026

22 December 2025133 pages

Choose your research edition.

Industry ResearchChagas Disease Treatment Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Chagas Disease Treatment Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Chagas Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chagas Disease Treatment Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Chagas Disease Treatment Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Chagas Disease Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Chagas Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Chagas Disease Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Chagas Disease Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Chagas Disease Treatment include Daiichi Sankyo Company Ltd, Eisai Co Ltd, ELEA SACIF Laboratory, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Grupo Praxis Pharmaceutical SA, KaloBios Pharmaceuticals, Inc, Kancera AB and Laboratorio Elea Phoenix SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Chagas Disease Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Chagas Disease Treatment Market by Company

Daiichi Sankyo Company Ltd

Eisai Co Ltd

ELEA SACIF Laboratory

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Grupo Praxis Pharmaceutical SA

KaloBios Pharmaceuticals, Inc

Kancera AB

Laboratorio Elea Phoenix SA

Laboratorio Farmaceutico De Pernambuco

Maprimed S.A

Nortec Quimica SA

Novartis AG

Oblita Therapeutics BVBA

Sanofi Aventis

AstraZeneca

Bayer AG

Johnson & Johnson

Chagas Disease Treatment Segment by Type

Benznidazole

Nifurtimox

Chagas Disease Treatment Segment by Application

Hospitals

Online Pharmacies

Retail Pharmacies

Chagas Disease Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chagas Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chagas Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chagas Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Chagas Disease Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Chagas Disease Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Chagas Disease Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Chagas Disease Treatment Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Chagas Disease Treatment Sales (k units) of Manufacturers (2021-2026) Table 7. Global Chagas Disease Treatment Sales Market Share by Manufacturers (2021-2026) Table 8. Global Chagas Disease Treatment Revenue of Manufacturers (2021-2026) Table 9. Global Chagas Disease Treatment Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Chagas Disease Treatment Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Chagas Disease Treatment Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Chagas Disease Treatment, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Chagas Disease Treatment, Product Type & Application Table 14. Global Chagas Disease Treatment Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Chagas Disease Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Daiichi Sankyo Company Ltd Company Information Table 19. Daiichi Sankyo Company Ltd Business Overview Table 20. Daiichi Sankyo Company Ltd Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Daiichi Sankyo Company Ltd Chagas Disease Treatment Product Portfolio Table 22. Daiichi Sankyo Company Ltd Recent Developments Table 23. Eisai Co Ltd Company Information Table 24. Eisai Co Ltd Business Overview Table 25. Eisai Co Ltd Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Eisai Co Ltd Chagas Disease Treatment Product Portfolio Table 27. Eisai Co Ltd Recent Developments Table 28. ELEA SACIF Laboratory Company Information Table 29. ELEA SACIF Laboratory Business Overview Table 30. ELEA SACIF Laboratory Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. ELEA SACIF Laboratory Chagas Disease Treatment Product Portfolio Table 32. ELEA SACIF Laboratory Recent Developments Table 33. F. Hoffmann-La Roche Ltd. Company Information Table 34. F. Hoffmann-La Roche Ltd. Business Overview Table 35. F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Product Portfolio Table 37. F. Hoffmann-La Roche Ltd. Recent Developments Table 38. GlaxoSmithKline Plc Company Information Table 39. GlaxoSmithKline Plc Business Overview Table 40. GlaxoSmithKline Plc Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. GlaxoSmithKline Plc Chagas Disease Treatment Product Portfolio Table 42. GlaxoSmithKline Plc Recent Developments Table 43. Grupo Praxis Pharmaceutical SA Company Information Table 44. Grupo Praxis Pharmaceutical SA Business Overview Table 45. Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Product Portfolio Table 47. Grupo Praxis Pharmaceutical SA Recent Developments Table 48. KaloBios Pharmaceuticals, Inc Company Information Table 49. KaloBios Pharmaceuticals, Inc Business Overview Table 50. KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Product Portfolio Table 52. KaloBios Pharmaceuticals, Inc Recent Developments Table 53. Kancera AB Company Information Table 54. Kancera AB Business Overview Table 55. Kancera AB Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Kancera AB Chagas Disease Treatment Product Portfolio Table 57. Kancera AB Recent Developments Table 58. Laboratorio Elea Phoenix SA Company Information Table 59. Laboratorio Elea Phoenix SA Business Overview Table 60. Laboratorio Elea Phoenix SA Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Laboratorio Elea Phoenix SA Chagas Disease Treatment Product Portfolio Table 62. Laboratorio Elea Phoenix SA Recent Developments Table 63. Laboratorio Farmaceutico De Pernambuco Company Information Table 64. Laboratorio Farmaceutico De Pernambuco Business Overview Table 65. Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Product Portfolio Table 67. Laboratorio Farmaceutico De Pernambuco Recent Developments Table 68. Maprimed S.A Company Information Table 69. Maprimed S.A Business Overview Table 70. Maprimed S.A Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Maprimed S.A Chagas Disease Treatment Product Portfolio Table 72. Maprimed S.A Recent Developments Table 73. Nortec Quimica SA Company Information Table 74. Nortec Quimica SA Business Overview Table 75. Nortec Quimica SA Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Nortec Quimica SA Chagas Disease Treatment Product Portfolio Table 77. Nortec Quimica SA Recent Developments Table 78. Novartis AG Company Information Table 79. Novartis AG Business Overview Table 80. Novartis AG Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Novartis AG Chagas Disease Treatment Product Portfolio Table 82. Novartis AG Recent Developments Table 83. Oblita Therapeutics BVBA Company Information Table 84. Oblita Therapeutics BVBA Business Overview Table 85. Oblita Therapeutics BVBA Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Oblita Therapeutics BVBA Chagas Disease Treatment Product Portfolio Table 87. Oblita Therapeutics BVBA Recent Developments Table 88. Sanofi Aventis Company Information Table 89. Sanofi Aventis Business Overview Table 90. Sanofi Aventis Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Sanofi Aventis Chagas Disease Treatment Product Portfolio Table 92. Sanofi Aventis Recent Developments Table 93. AstraZeneca Company Information Table 94. AstraZeneca Business Overview Table 95. AstraZeneca Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. AstraZeneca Chagas Disease Treatment Product Portfolio Table 97. AstraZeneca Recent Developments Table 98. Bayer AG Company Information Table 99. Bayer AG Business Overview Table 100. Bayer AG Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Bayer AG Chagas Disease Treatment Product Portfolio Table 102. Bayer AG Recent Developments Table 103. Johnson & Johnson Company Information Table 104. Johnson & Johnson Business Overview Table 105. Johnson & Johnson Chagas Disease Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Johnson & Johnson Chagas Disease Treatment Product Portfolio Table 107. Johnson & Johnson Recent Developments Table 108. Global Chagas Disease Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Chagas Disease Treatment Sales by Region (2021-2026) & (k units) Table 110. Global Chagas Disease Treatment Sales Market Share by Region (2021-2026) Table 111. Global Chagas Disease Treatment Sales by Region (2027-2032) & (k units) Table 112. Global Chagas Disease Treatment Sales Market Share by Region (2027-2032) Table 113. Global Chagas Disease Treatment Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Chagas Disease Treatment Revenue Market Share by Region (2021-2026) Table 115. Global Chagas Disease Treatment Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Chagas Disease Treatment Revenue Market Share by Region (2027-2032) Table 117. North America Chagas Disease Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Chagas Disease Treatment Sales by Country (2021-2026) & (k units) Table 119. North America Chagas Disease Treatment Sales by Country (2027-2032) & (k units) Table 120. North America Chagas Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Chagas Disease Treatment Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Chagas Disease Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Chagas Disease Treatment Sales by Country (2021-2026) & (k units) Table 124. Europe Chagas Disease Treatment Sales by Country (2027-2032) & (k units) Table 125. Europe Chagas Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Chagas Disease Treatment Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Chagas Disease Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Chagas Disease Treatment Sales by Country (2021-2026) & (k units) Table 129. Asia Pacific Chagas Disease Treatment Sales by Country (2027-2032) & (k units) Table 130. Asia Pacific Chagas Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Chagas Disease Treatment Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Chagas Disease Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Chagas Disease Treatment Sales by Country (2021-2026) & (k units) Table 134. South America Chagas Disease Treatment Sales by Country (2027-2032) & (k units) Table 135. South America Chagas Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Chagas Disease Treatment Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Chagas Disease Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Chagas Disease Treatment Sales by Country (2021-2026) & (k units) Table 139. Middle East and Africa Chagas Disease Treatment Sales by Country (2027-2032) & (k units) Table 140. Middle East and Africa Chagas Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Chagas Disease Treatment Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Chagas Disease Treatment Sales by Type (2021-2026) & (k units) Table 143. Global Chagas Disease Treatment Sales by Type (2027-2032) & (k units) Table 144. Global Chagas Disease Treatment Sales Market Share by Type (2021-2026) Table 145. Global Chagas Disease Treatment Sales Market Share by Type (2027-2032) Table 146. Global Chagas Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Chagas Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Chagas Disease Treatment Revenue Market Share by Type (2021-2026) Table 149. Global Chagas Disease Treatment Revenue Market Share by Type (2027-2032) Table 150. Global Chagas Disease Treatment Price by Type (2021-2026) & (US$/unit) Table 151. Global Chagas Disease Treatment Price by Type (2027-2032) & (US$/unit) Table 152. Global Chagas Disease Treatment Sales by Application (2021-2026) & (k units) Table 153. Global Chagas Disease Treatment Sales by Application (2027-2032) & (k units) Table 154. Global Chagas Disease Treatment Sales Market Share by Application (2021-2026) Table 155. Global Chagas Disease Treatment Sales Market Share by Application (2027-2032) Table 156. Global Chagas Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Chagas Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Chagas Disease Treatment Revenue Market Share by Application (2021-2026) Table 159. Global Chagas Disease Treatment Revenue Market Share by Application (2027-2032) Table 160. Global Chagas Disease Treatment Price by Application (2021-2026) & (US$/unit) Table 161. Global Chagas Disease Treatment Price by Application (2027-2032) & (US$/unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Chagas Disease Treatment Distributors List Table 165. Chagas Disease Treatment Customers List Table 166. Chagas Disease Treatment Industry Trends Table 167. Chagas Disease Treatment Industry Drivers Table 168. Chagas Disease Treatment Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Chagas Disease Treatment Product Image Figure 5. Global Chagas Disease Treatment Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Chagas Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 7. Global Chagas Disease Treatment Sales (2021-2032) & (k units) Figure 8. Global Chagas Disease Treatment Average Price (US$/unit) & (2021-2032) Figure 9. Benznidazole Product Image Figure 10. Nifurtimox Product Image Figure 11. Hospitals Product Image Figure 12. Online Pharmacies Product Image Figure 13. Retail Pharmacies Product Image Figure 14. Global Chagas Disease Treatment Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Chagas Disease Treatment, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Chagas Disease Treatment Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Chagas Disease Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Chagas Disease Treatment Sales by Region in 2025 Figure 20. Global Chagas Disease Treatment Revenue by Region in 2025 Figure 21. North America Chagas Disease Treatment Market Size by Country in 2025 Figure 22. North America Chagas Disease Treatment Sales Market Share by Country (2021-2032) Figure 23. North America Chagas Disease Treatment Revenue Market Share by Country (2021-2032) Figure 24. United States Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Chagas Disease Treatment Market Size by Country in 2025 Figure 28. Europe Chagas Disease Treatment Sales Market Share by Country (2021-2032) Figure 29. Europe Chagas Disease Treatment Revenue Market Share by Country (2021-2032) Figure 30. Germany Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Chagas Disease Treatment Market Size by Country in 2025 Figure 41. Asia Pacific Chagas Disease Treatment Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Chagas Disease Treatment Revenue Market Share by Country (2021-2032) Figure 43. China Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Chagas Disease Treatment Market Size by Country in 2025 Figure 52. South America Chagas Disease Treatment Sales Market Share by Country (2021-2032) Figure 53. South America Chagas Disease Treatment Revenue Market Share by Country (2021-2032) Figure 54. Brazil Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Chagas Disease Treatment Market Size by Country in 2025 Figure 58. Middle East and Africa Chagas Disease Treatment Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Chagas Disease Treatment Revenue Market Share by Country (2021-2032) Figure 60. Egypt Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Chagas Disease Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Chagas Disease Treatment Sales Market Share by Type (2021-2032) Figure 66. Global Chagas Disease Treatment Revenue Market Share by Type (2021-2032) Figure 67. Global Chagas Disease Treatment Price (US$/unit) by Type (2021-2032) Figure 68. Global Chagas Disease Treatment Sales Market Share by Application (2021-2032) Figure 69. Global Chagas Disease Treatment Revenue Market Share by Application (2021-2032) Figure 70. Global Chagas Disease Treatment Price (US$/unit) by Application (2021-2032) Figure 71. Chagas Disease Treatment Value Chain Figure 72. Chagas Disease Treatment Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Chagas Disease Treatment Industry Opportunities and Challenges

Scope & coverage.

Types
  • Benznidazole
  • Nifurtimox
Applications
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Daiichi Sankyo Company Ltd
  • Eisai Co Ltd
  • ELEA SACIF Laboratory
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Grupo Praxis Pharmaceutical SA
  • KaloBios Pharmaceuticals, Inc
  • Kancera AB
  • Laboratorio Elea Phoenix SA
  • Laboratorio Farmaceutico De Pernambuco
  • Maprimed S.A
  • Nortec Quimica SA
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Sanofi Aventis
  • AstraZeneca
  • Bayer AG
  • Johnson & Johnson

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Chagas Disease Treatment Market Size (2021-2032)
  4. 2.2.2 Global Chagas Disease Treatment Sales (2021-2032)
  5. 2.2.3 Global Chagas Disease Treatment Market Average Price (2021-2032)
  6. 2.3 Chagas Disease Treatment by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Benznidazole
  9. 2.3.3 Nifurtimox
  10. 2.4 Chagas Disease Treatment by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospitals
  13. 2.4.3 Online Pharmacies
  14. 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Chagas Disease Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Chagas Disease Treatment Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Chagas Disease Treatment Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Chagas Disease Treatment Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Chagas Disease Treatment Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Chagas Disease Treatment, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Chagas Disease Treatment, Product Type & Application
  8. 3.8 Global Manufacturers of Chagas Disease Treatment, Established Date
  9. 3.9 Global Chagas Disease Treatment Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Daiichi Sankyo Company Ltd
  2. 4.1.1 Daiichi Sankyo Company Ltd Company Information
  3. 4.1.2 Daiichi Sankyo Company Ltd Business Overview
  4. 4.1.3 Daiichi Sankyo Company Ltd Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Daiichi Sankyo Company Ltd Chagas Disease Treatment Product Portfolio
  6. 4.1.5 Daiichi Sankyo Company Ltd Recent Developments
  7. 4.2 Eisai Co Ltd
  8. 4.2.1 Eisai Co Ltd Company Information
  9. 4.2.2 Eisai Co Ltd Business Overview
  10. 4.2.3 Eisai Co Ltd Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Eisai Co Ltd Chagas Disease Treatment Product Portfolio
  12. 4.2.5 Eisai Co Ltd Recent Developments
  13. 4.3 ELEA SACIF Laboratory
  14. 4.3.1 ELEA SACIF Laboratory Company Information
  15. 4.3.2 ELEA SACIF Laboratory Business Overview
  16. 4.3.3 ELEA SACIF Laboratory Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 ELEA SACIF Laboratory Chagas Disease Treatment Product Portfolio
  18. 4.3.5 ELEA SACIF Laboratory Recent Developments
  19. 4.4 F. Hoffmann-La Roche Ltd.
  20. 4.4.1 F. Hoffmann-La Roche Ltd. Company Information
  21. 4.4.2 F. Hoffmann-La Roche Ltd. Business Overview
  22. 4.4.3 F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Product Portfolio
  24. 4.4.5 F. Hoffmann-La Roche Ltd. Recent Developments
  25. 4.5 GlaxoSmithKline Plc
  26. 4.5.1 GlaxoSmithKline Plc Company Information
  27. 4.5.2 GlaxoSmithKline Plc Business Overview
  28. 4.5.3 GlaxoSmithKline Plc Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 GlaxoSmithKline Plc Chagas Disease Treatment Product Portfolio
  30. 4.5.5 GlaxoSmithKline Plc Recent Developments
  31. 4.6 Grupo Praxis Pharmaceutical SA
  32. 4.6.1 Grupo Praxis Pharmaceutical SA Company Information
  33. 4.6.2 Grupo Praxis Pharmaceutical SA Business Overview
  34. 4.6.3 Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Product Portfolio
  36. 4.6.5 Grupo Praxis Pharmaceutical SA Recent Developments
  37. 4.7 KaloBios Pharmaceuticals, Inc
  38. 4.7.1 KaloBios Pharmaceuticals, Inc Company Information
  39. 4.7.2 KaloBios Pharmaceuticals, Inc Business Overview
  40. 4.7.3 KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Product Portfolio
  42. 4.7.5 KaloBios Pharmaceuticals, Inc Recent Developments
  43. 4.8 Kancera AB
  44. 4.8.1 Kancera AB Company Information
  45. 4.8.2 Kancera AB Business Overview
  46. 4.8.3 Kancera AB Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Kancera AB Chagas Disease Treatment Product Portfolio
  48. 4.8.5 Kancera AB Recent Developments
  49. 4.9 Laboratorio Elea Phoenix SA
  50. 4.9.1 Laboratorio Elea Phoenix SA Company Information
  51. 4.9.2 Laboratorio Elea Phoenix SA Business Overview
  52. 4.9.3 Laboratorio Elea Phoenix SA Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Laboratorio Elea Phoenix SA Chagas Disease Treatment Product Portfolio
  54. 4.9.5 Laboratorio Elea Phoenix SA Recent Developments
  55. 4.10 Laboratorio Farmaceutico De Pernambuco
  56. 4.10.1 Laboratorio Farmaceutico De Pernambuco Company Information
  57. 4.10.2 Laboratorio Farmaceutico De Pernambuco Business Overview
  58. 4.10.3 Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Product Portfolio
  60. 4.10.5 Laboratorio Farmaceutico De Pernambuco Recent Developments
  61. 4.11 Maprimed S.A
  62. 4.11.1 Maprimed S.A Company Information
  63. 4.11.2 Maprimed S.A Business Overview
  64. 4.11.3 Maprimed S.A Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Maprimed S.A Chagas Disease Treatment Product Portfolio
  66. 4.11.5 Maprimed S.A Recent Developments
  67. 4.12 Nortec Quimica SA
  68. 4.12.1 Nortec Quimica SA Company Information
  69. 4.12.2 Nortec Quimica SA Business Overview
  70. 4.12.3 Nortec Quimica SA Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Nortec Quimica SA Chagas Disease Treatment Product Portfolio
  72. 4.12.5 Nortec Quimica SA Recent Developments
  73. 4.13 Novartis AG
  74. 4.13.1 Novartis AG Company Information
  75. 4.13.2 Novartis AG Business Overview
  76. 4.13.3 Novartis AG Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Novartis AG Chagas Disease Treatment Product Portfolio
  78. 4.13.5 Novartis AG Recent Developments
  79. 4.14 Oblita Therapeutics BVBA
  80. 4.14.1 Oblita Therapeutics BVBA Company Information
  81. 4.14.2 Oblita Therapeutics BVBA Business Overview
  82. 4.14.3 Oblita Therapeutics BVBA Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Oblita Therapeutics BVBA Chagas Disease Treatment Product Portfolio
  84. 4.14.5 Oblita Therapeutics BVBA Recent Developments
  85. 4.15 Sanofi Aventis
  86. 4.15.1 Sanofi Aventis Company Information
  87. 4.15.2 Sanofi Aventis Business Overview
  88. 4.15.3 Sanofi Aventis Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Sanofi Aventis Chagas Disease Treatment Product Portfolio
  90. 4.15.5 Sanofi Aventis Recent Developments
  91. 4.16 AstraZeneca
  92. 4.16.1 AstraZeneca Company Information
  93. 4.16.2 AstraZeneca Business Overview
  94. 4.16.3 AstraZeneca Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 AstraZeneca Chagas Disease Treatment Product Portfolio
  96. 4.16.5 AstraZeneca Recent Developments
  97. 4.17 Bayer AG
  98. 4.17.1 Bayer AG Company Information
  99. 4.17.2 Bayer AG Business Overview
  100. 4.17.3 Bayer AG Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Bayer AG Chagas Disease Treatment Product Portfolio
  102. 4.17.5 Bayer AG Recent Developments
  103. 4.18 Johnson & Johnson
  104. 4.18.1 Johnson & Johnson Company Information
  105. 4.18.2 Johnson & Johnson Business Overview
  106. 4.18.3 Johnson & Johnson Chagas Disease Treatment Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Johnson & Johnson Chagas Disease Treatment Product Portfolio
  108. 4.18.5 Johnson & Johnson Recent Developments
5 Global Chagas Disease Treatment Market Scenario by Region
  1. 5.1 Global Chagas Disease Treatment Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Chagas Disease Treatment Sales by Region: 2021-2032
  3. 5.2.1 Global Chagas Disease Treatment Sales by Region: 2021-2026
  4. 5.2.2 Global Chagas Disease Treatment Sales by Region: 2027-2032
  5. 5.3 Global Chagas Disease Treatment Revenue by Region: 2021-2032
  6. 5.3.1 Global Chagas Disease Treatment Revenue by Region: 2021-2026
  7. 5.3.2 Global Chagas Disease Treatment Revenue by Region: 2027-2032
  8. 5.4 North America Chagas Disease Treatment Market Facts & Figures by Country
  9. 5.4.1 North America Chagas Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Chagas Disease Treatment Sales by Country (2021-2032)
  11. 5.4.3 North America Chagas Disease Treatment Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Chagas Disease Treatment Market Facts & Figures by Country
  16. 5.5.1 Europe Chagas Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Chagas Disease Treatment Sales by Country (2021-2032)
  18. 5.5.3 Europe Chagas Disease Treatment Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Chagas Disease Treatment Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Chagas Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Chagas Disease Treatment Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Chagas Disease Treatment Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Chagas Disease Treatment Market Facts & Figures by Country
  41. 5.7.1 South America Chagas Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Chagas Disease Treatment Sales by Country (2021-2032)
  43. 5.7.3 South America Chagas Disease Treatment Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Chagas Disease Treatment Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Chagas Disease Treatment Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Chagas Disease Treatment Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Chagas Disease Treatment Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Chagas Disease Treatment Sales by Type (2021-2032)
  2. 6.1.1 Global Chagas Disease Treatment Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Chagas Disease Treatment Sales Market Share by Type (2021-2032)
  4. 6.2 Global Chagas Disease Treatment Revenue by Type (2021-2032)
  5. 6.2.1 Global Chagas Disease Treatment Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Chagas Disease Treatment Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Chagas Disease Treatment Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Chagas Disease Treatment Sales by Application (2021-2032)
  2. 7.1.1 Global Chagas Disease Treatment Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Chagas Disease Treatment Sales Market Share by Application (2021-2032)
  4. 7.2 Global Chagas Disease Treatment Revenue by Application (2021-2032)
  5. 7.2.1 Global Chagas Disease Treatment Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Chagas Disease Treatment Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Chagas Disease Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Chagas Disease Treatment Value Chain Analysis
  2. 8.1.1 Chagas Disease Treatment Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Chagas Disease Treatment Production Mode & Process
  5. 8.2 Chagas Disease Treatment Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Chagas Disease Treatment Distributors
  8. 8.2.3 Chagas Disease Treatment Customers
9 Global Chagas Disease Treatment Analyzing Market Dynamics
  1. 9.1 Chagas Disease Treatment Industry Trends
  2. 9.2 Chagas Disease Treatment Industry Drivers
  3. 9.3 Chagas Disease Treatment Industry Opportunities and Challenges
  4. 9.4 Chagas Disease Treatment Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst